[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pulnovo Medical (Wuxi) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":13,"conditions":21,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100595988","real-world-study-of-padn-for-the-treatment-of-pah-100595988",false,"NCT07039604","Real-World Study of PADN for the Treatment of PAH","Real-World Study of Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Arterial Hypertension (PAH)","Inclusion Criteria:\n\n1. Diagnosed with PAH and received PADN procedure since March 2024.\n2. No contraindications to procedure.\n3. Able to provide informed consent and authorize use of health\u002Fresearch data.\n4. Compliant with treatment and follow-up requirements.\n\nExclusion Criteria:\n\nNone specified.","ALL",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL",[22,23],"Pulmonary Hypertension","Hypertension, Pulmonary Arterial","RECRUITING","2025-06-17",{"date":27,"type":28},"2025-06-26","ACTUAL",{"date":30,"type":28},"2025-03-19",{"date":32,"type":19},"2028-12-30",{"name":34,"class":35},"Pulnovo Medical (Wuxi) Co., Ltd.","INDUSTRY",""]